Investigations
One of the challenges of Phenotypingt is that too little clinical information is available as machine-readable data sets. Admission letters, findings and operating room reports in particular contain valuable information such as diagnoses, medications, side effects and laboratory data that can only be extracted using methods of natural language processing and semantic text analysis methods. Natural Language Processing (NLP) is used to process documents from the Hospital Information System (HIS). ...
PheP is a platform that enables clinical researchers to work together with statisticians and computer scientists in interdisciplinary collaboration to pursue scientific issues that previously seemed economically and technologically unthinkable. For this purpose, it is necessary to build data sets that can be used for clinical-epidemiological and health-economic issues.
From phenotypes, i.e. determinable characteristics of patients, further characteristics can be derived and provided via phenotyping. ...
Test data for POLAR and other use cases
Submitter: Frank A. Meineke
Studies: FHIR Test Data
Resources: General FHIR Test Data, POLAR, Vorhofflimmern
The aim of this investigation is to develop a methodology to model and express phenotype classes. These models can be used to generate queries to search for individuals (patients or study participants) with specific phenotypes.
Submitter: Christoph Beger
Studies: Ontology-based Phenotype Knowledge Model
Resources: Example Phenotype Specification Ontology for Inclusion Criteria Hyperten...
Ressource related to the information architecture subsuming the central FAIR4Health Platform and the local FAIR4Health agents.
Submitter: Matthias Löbe
Studies: 3LGM² model for FAIR4Health
Resources: 3LGM² local model DIC Leipzig, 3LGM² model survey, 3LGM² reference model, Diagram inter-level relationships
Submitter: Matthias Löbe
Studies: #1 Characterization of multimorbidity patterns and association with heal...
Resources: Clinical Dataset
Resutls of different OMICS-level using LIFE Adult and LIFE Heart data are presented (Publications, Supplemental Data, & Summary Statistics).
Submitter: René Hänsel
Studies: DNA methylation patterns reflect individual lifestyle independent from o..., GWAMA PCSK9, GWAMA Phytosterole, GWAMA Steroid hormones, GWAMA vaspin, GWAS Body Scanner Measures, GWAS Carotid Plaque Burden, GWAS Pulse Wave Velocity, GWAS Steroid Hormones, scRNA-Seq across species for pulmonologists
Resources: Gene Expression data, LIFE-Adult EPIC data, Summary Statistic for PWV GWAS, Summary Statistics, Summary Statistics, Summary Statistics, Summary Statistics, Summary Statistics, Summary Statistics - Phytosterols, Supplement Data, scRNA-Seq expression data as RDS Seurat file
Submitter: Alexandr Uciteli
Studies: Ontological Modelling of Basic Eligibility Criteria, Ontological Modelling of Type 2 Diabetes Mellitus (T2DM) Phenotype, PhenoMan Evaluation with Synthetic FHIR Data
Resources: Basic Eligibility Criteria of an Example Blood Pressure Study, Ontological Modelling of T2DM Phenotype using Phenotype Manager (PhenoMan), PhenoMan Evaluation - Synthetic FHIR Data
Severe sepsis and septic shock have a high mortality. Research has concentrated on adjunctive sepsis therapies; the role of supportive measures is comparatively unclear. In Europe the use of colloids is widespread, but there is no evidence on the role of either crystalloid or colloid volume therapy in sepsis. Recently, a higher incidence of kidney failure in sepsis was reported after administration of colloids.
Stratification of head and neck squamous cell carcinomas (HNSCC) based on HPV16 DNA and RNA status
ROF filter based segmentation methods will be employed for automated recognition of macrophages, B-cells and cell nuclei within the tissue samples.
Mega-CHOEP phase III is a randomised study comparing conventional chemoimmunotherapy with R-CHOEP-14 with high-dose chemotherapy plus Rituximab with autologous stem cell transplantation in high-risk patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.
RICOVER-60 is a randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody Rituximab in patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.
Submitter: René Hänsel
Studies: RICOVER-60
Resources: RICOVER-60 trial data, RICOVER-60 trial metadata
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Submitter: René Hänsel
Studies: SEXIE-R-CHOP-14
Resources: SEXIE-R-CHOP-14 metadata, SEXIE-R-CHOP-14 trial data
Submitter: René Hänsel
Studies: SMARTE-R-CHOP-14
Resources: SMARTE-R-CHOP-14 metadata, SMARTE-R-CHOP-14 trial data
Submitter: René Hänsel
Studies: RICOVER-noRTh
Resources: RICOVER-noRTh metadata, RICOVER-noRTh trial data
Submitter: René Hänsel
Studies: Pegfilgrastim
Resources: Pegfilgrastim metadata, Pegfilgrastim trial data
Submitter: René Hänsel
Studies: DENSE-R-CHOP-14
Resources: DENSE-R-CHOP-14 trial data, DENSE-R-CHOP-14 trial metadata
The toxcalculator is a web-based tool to calculate prognostic scores on haematopoietic toxicity for 6 cycles CHOP-like regimen in patients with aggressive NHL. The models used for the toxcalculator are based on data obtained in the NHL-B1 and NHL-B2-trials, validated with the RICOVER-60-dataset.
